Bromocryptine is a drug that has been approved for a long time for treatment of other conditions. It has recently been
approved by the FDA for use in
type 2 diabetes.
bromocryptine
- Brand name in US: Cycloset®
- Class: dopamine receptor agonist
- For: Type 2 diabetes
- Route of Administration: oral. Available as 0.8 mg tablet; maximal recommended dose of 6 tablets (4.8 mg) daily.
- Action:
works in the brain "to reset hypothalamic centers regulating postprandial insulin-mediated glucose and lipid metabolism to thereby reduce postprandial hyperglycemia and hyperlipidemia."
- Manufacturer: Veroscience
- Status: Approved in USA May 2009
- Source: Information from manufacturer
Veroscience; Cycloset prescribing information (see below).
- Side effects:
Orthostatic hypotension (low blood pressure upon standing), nausea, fatigue, dizziness, vomiting, and headache. Postmarketing reports with higher doses of bromocriptine used for other indications include psychotic disorders, hallucinations, and fibrotic complications.
- Other drugs in the same class: none
Also see
Cycloset prescribing information at FDA website ([PDF file]
VeroScience's Cycloset Gets FDA Nod in Type II Diabetes
at BioWorld
Under the radar
By William Quick
Bromocriptine and hibernation
By Gretchen Becker
|
|
|
